Antitumor activity of tributyrin in murine melanoma model

Adam Giermasz, Dominika Nowis, Ahmad Jalili, Grzegorz Basak, Maria Marczak, Marcin Makowski, Anna Czajka, Izabela Mlynarczuk, Grayna Hoser, Tomasz Stok osa, Sebastian Lewandowski, Marek Jakóbisiak

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Butyric acid has been known to inhibit growth and to induce differentiation of a variety of tumor cells. Butyrate-treated tumor cells have also been observed to undergo apoptosis. Although butyrate compounds have demonstrated antitumor activity in murine tumor models and have already been admitted to clinical trials in tumor patients, the exact mechanism of their antitumor effects has not been elucidated. The results of our study showed antitumor activity of tributyrin, a butyric acid prodrug, in murine melanoma model and are strongly suggestive that antiangiogenic effects could participate in antitumor effects of butyrate compounds in vivo.

Original languageEnglish (US)
Pages (from-to)143-148
Number of pages6
JournalCancer Letters
Volume164
Issue number2
DOIs
StatePublished - Mar 26 2001
Externally publishedYes

Fingerprint

Butyrates
Melanoma
Butyric Acid
Neoplasms
Prodrugs
Clinical Trials
Apoptosis
tributyrin
Growth

Keywords

  • Butyrate
  • Melanoma
  • Mouse
  • Tributyrin
  • Tumor therapy

ASJC Scopus subject areas

  • Cancer Research
  • Molecular Biology
  • Oncology

Cite this

Giermasz, A., Nowis, D., Jalili, A., Basak, G., Marczak, M., Makowski, M., ... Jakóbisiak, M. (2001). Antitumor activity of tributyrin in murine melanoma model. Cancer Letters, 164(2), 143-148. https://doi.org/10.1016/S0304-3835(01)00375-5

Antitumor activity of tributyrin in murine melanoma model. / Giermasz, Adam; Nowis, Dominika; Jalili, Ahmad; Basak, Grzegorz; Marczak, Maria; Makowski, Marcin; Czajka, Anna; Mlynarczuk, Izabela; Hoser, Grayna; Stok osa, Tomasz; Lewandowski, Sebastian; Jakóbisiak, Marek.

In: Cancer Letters, Vol. 164, No. 2, 26.03.2001, p. 143-148.

Research output: Contribution to journalArticle

Giermasz, A, Nowis, D, Jalili, A, Basak, G, Marczak, M, Makowski, M, Czajka, A, Mlynarczuk, I, Hoser, G, Stok osa, T, Lewandowski, S & Jakóbisiak, M 2001, 'Antitumor activity of tributyrin in murine melanoma model', Cancer Letters, vol. 164, no. 2, pp. 143-148. https://doi.org/10.1016/S0304-3835(01)00375-5
Giermasz A, Nowis D, Jalili A, Basak G, Marczak M, Makowski M et al. Antitumor activity of tributyrin in murine melanoma model. Cancer Letters. 2001 Mar 26;164(2):143-148. https://doi.org/10.1016/S0304-3835(01)00375-5
Giermasz, Adam ; Nowis, Dominika ; Jalili, Ahmad ; Basak, Grzegorz ; Marczak, Maria ; Makowski, Marcin ; Czajka, Anna ; Mlynarczuk, Izabela ; Hoser, Grayna ; Stok osa, Tomasz ; Lewandowski, Sebastian ; Jakóbisiak, Marek. / Antitumor activity of tributyrin in murine melanoma model. In: Cancer Letters. 2001 ; Vol. 164, No. 2. pp. 143-148.
@article{71f6c810653248bc97316034394675ff,
title = "Antitumor activity of tributyrin in murine melanoma model",
abstract = "Butyric acid has been known to inhibit growth and to induce differentiation of a variety of tumor cells. Butyrate-treated tumor cells have also been observed to undergo apoptosis. Although butyrate compounds have demonstrated antitumor activity in murine tumor models and have already been admitted to clinical trials in tumor patients, the exact mechanism of their antitumor effects has not been elucidated. The results of our study showed antitumor activity of tributyrin, a butyric acid prodrug, in murine melanoma model and are strongly suggestive that antiangiogenic effects could participate in antitumor effects of butyrate compounds in vivo.",
keywords = "Butyrate, Melanoma, Mouse, Tributyrin, Tumor therapy",
author = "Adam Giermasz and Dominika Nowis and Ahmad Jalili and Grzegorz Basak and Maria Marczak and Marcin Makowski and Anna Czajka and Izabela Mlynarczuk and Grayna Hoser and {Stok osa}, Tomasz and Sebastian Lewandowski and Marek Jak{\'o}bisiak",
year = "2001",
month = "3",
day = "26",
doi = "10.1016/S0304-3835(01)00375-5",
language = "English (US)",
volume = "164",
pages = "143--148",
journal = "Cancer Letters",
issn = "0304-3835",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

TY - JOUR

T1 - Antitumor activity of tributyrin in murine melanoma model

AU - Giermasz, Adam

AU - Nowis, Dominika

AU - Jalili, Ahmad

AU - Basak, Grzegorz

AU - Marczak, Maria

AU - Makowski, Marcin

AU - Czajka, Anna

AU - Mlynarczuk, Izabela

AU - Hoser, Grayna

AU - Stok osa, Tomasz

AU - Lewandowski, Sebastian

AU - Jakóbisiak, Marek

PY - 2001/3/26

Y1 - 2001/3/26

N2 - Butyric acid has been known to inhibit growth and to induce differentiation of a variety of tumor cells. Butyrate-treated tumor cells have also been observed to undergo apoptosis. Although butyrate compounds have demonstrated antitumor activity in murine tumor models and have already been admitted to clinical trials in tumor patients, the exact mechanism of their antitumor effects has not been elucidated. The results of our study showed antitumor activity of tributyrin, a butyric acid prodrug, in murine melanoma model and are strongly suggestive that antiangiogenic effects could participate in antitumor effects of butyrate compounds in vivo.

AB - Butyric acid has been known to inhibit growth and to induce differentiation of a variety of tumor cells. Butyrate-treated tumor cells have also been observed to undergo apoptosis. Although butyrate compounds have demonstrated antitumor activity in murine tumor models and have already been admitted to clinical trials in tumor patients, the exact mechanism of their antitumor effects has not been elucidated. The results of our study showed antitumor activity of tributyrin, a butyric acid prodrug, in murine melanoma model and are strongly suggestive that antiangiogenic effects could participate in antitumor effects of butyrate compounds in vivo.

KW - Butyrate

KW - Melanoma

KW - Mouse

KW - Tributyrin

KW - Tumor therapy

UR - http://www.scopus.com/inward/record.url?scp=0035953181&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035953181&partnerID=8YFLogxK

U2 - 10.1016/S0304-3835(01)00375-5

DO - 10.1016/S0304-3835(01)00375-5

M3 - Article

C2 - 11179828

AN - SCOPUS:0035953181

VL - 164

SP - 143

EP - 148

JO - Cancer Letters

JF - Cancer Letters

SN - 0304-3835

IS - 2

ER -